comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 12:34:35 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： CDC panel: People 65 and older should get a Covid spring booster shot

WSS

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Longer MASH drug regimen improved liver, Akero study finds

$1 billion proposal to grow Boston, Massachusetts biotech

Childhood vaccination ad campaign launches in the U.K.

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Pfizer is about to make a big push in cancer. Will investors listen?

Wikipedia

comprehensive

leisure time

Walensky prepares to leave CDC — and Congress — behind

Neuroscience renaissance leads to new crop of psychiatric drugs

Novavax promises a turnaround & Lilly roils the obesity market

Childhood vaccination ad campaign launches in the U.K.

DIEP, the 'gold standard' of breast reconstruction, is under threat

Lack of health data on LGBTQ+ people has serious consequences

How one medical school became remarkably diverse

Ozempic has benefits for kidney disease as well as diabetes

At least 13 dead in Texas as scorching temps continue

Ohio train derailment: Experts on toxic chemical risks

hotspot

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medicare Advantage isn’t working — for anyone

Doctor of U.S. President Joe Biden says he is fit for duty

5 ways to address the shortage of health care workers

Redefining sustainability for the pharmaceutical industry

focus

Wikipedia

Wikipedia

Wikipedia